Stockreport

U.S. FDA Renews DILIsym® Software Licenses for 7th Year

Simulations Plus, Inc.  (SLP) 
Last simulations plus, inc. earnings: 4/9 04:35 pm Check Earnings Report
US:NASDAQ Investor Relations: simulations-plus.com/software/overview
PDF Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SL [Read more]